Ƶ

AI Predicts Alzheimer's; High-Profile Dementia; Let Kids With Concussion Use Their Phones

— News and commentary from the world of neurology and neuroscience

Ƶ MedicalToday

Artificial intelligence -- coupled with 18F-FDG PET imaging -- 6 years before final diagnosis, with a specificity of 82% and sensitivity of 100%. (Radiology)

A targeted ballet program improved balance and reduced ataxia in women with mild-to-moderate . (PLOS One)

The FDA decided Voyager's was not eligible for accelerated approval based on phase II data, which the agency now considers "exploratory." (Endpoints News)

Public disclosure by high-profile public figures like Sandra Day O'Connor, Ronald Reagan, and musician Glen Campbell have helped remove the . (New York Times)

Elevated cerebrospinal fluid (CSF) levels -- but not CSF total tau, phosphorylated tau, or neurogranin levels -- were associated with risk of mild cognitive impairment in a community population. (JAMA Neurology)

And an altered was associated with cognitive impairment in Alzheimer's disease. (Alzheimer's & Dementia)

Three relapsing-remitting multiple sclerosis patients developed (Lemtrada) for over a year. (Neurology)

The landmark (Onpattro), approved by the FDA in August to treat polyneuropathy in hereditary transthyretin amyloidosis patients, was off to a slow start with only 50 patients and $500,000 in sales in its first 7 weeks. (Boston Business Journal)

The American Academy of Pediatrics updated its to support light activity as children recover and discourage completely removing electronic devices, as "many young athletes are highly socially connected through their electronics and social media." (Pediatrics)

Eli Lilly scrapped a phase II Alzheimer's clinical trial for a , but is still studying the N3PG agent as monotherapy. (FierceBiotech)